Dexcom's safety notice is not a vague device scare, because FDA posted the company's warning that stolen scrapped Dexcom G7 sensors from two lots may have reached users, with one lot carrying infection risk and another carrying a no-reading risk. [1]

The paper's May 31 piece on FDA recalls as household tasks is the right frame: the reader action is not to mistrust every continuous glucose monitor, but to check the package, the lot, the seller, and the provenance before turning a household alert into generalized medtech dread.

The lots named in the research stack are 1725204004 and 1725069002, and the practical stakes are different but serious: one concern is that scrapped product may not have been sterile enough for safe use, while the other is that a sensor may fail to provide readings, which for a diabetes patient is not a theoretical failure mode. [1]

That is why lot checking matters more than outrage, since the danger is tied to specific inventory that should not have been in circulation, not to every sensor on a pharmacy shelf or every patient already using a properly sourced device.

FDA's broader recall page is useful because it keeps these alerts in one public place rather than scattering them across company statements and social posts, and device safety becomes real when the kitchen-table question is answerable: is this my lot, where did it come from, was it bought through a trusted channel, and what should I do next? [1] [2]

-- NORA WHITFIELD, Chicago